Ticker Launch
Sign inTry it free

Reverse merger · Completed · TECX

Tectonic Therapeutic, Inc.

Reverse merger with AVROBIO, Inc.

Tectonic Therapeutic, Inc. merged into AVROBIO, Inc., a Nasdaq-listed gene therapy biotech with inactive legacy programs sold for CVRs, in a reverse merger that takes the private company public. The deal was announced on Jan 30, 2024 and closed on Jun 20, 2024. The combined company trades as Tectonic Therapeutic, Inc. (TECX) on Nasdaq.

Tectonic Therapeutic is a clinical-stage biotechnology company developing GPCR-targeted biologic therapies. Lead program TX45, a Fc-relaxin fusion, is in Phase 1a/1b trials for Group 2 pulmonary hypertension with HFpEF, and a second program targets hereditary hemorrhagic telangiectasia.

Status
Completed
Private company
Tectonic Therapeutic, Inc.
Public company
AVROBIO, Inc.
Public company business before
Nasdaq-listed gene therapy biotech with inactive legacy programs sold for CVRs
Announced
Jan 30, 2024
Closed
Jun 20, 2024
Combined company
Tectonic Therapeutic, Inc. (TECX)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers